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Abstract: Ginsenoside Rh2, an intermediate metabolite of ginseng, but not naturally occurring,
has recently drawn attention because of its anticancer effect. However, it is not clear if and how Rh2
inhibits preadipocytes differentiation. In the present study, we hypothesized that ginsenoside Rh2
attenuates adipogenesis through regulating the peroxisome proliferator-activated receptor gamma
(PPAR-γ) pathway both in cells and obese mice. Different concentrations of Rh2 were applied both
in 3T3-L1 cells and human primary preadipocytes to determine if Rh2 inhibits cell differentiation.
Dietary Rh2 was administered to obese mice to determine if Rh2 prevents obesity in vivo. The mRNA
and protein expression of PPAR-γ pathway molecules in cells and tissues were measured by real-time
polymerase chain reaction (RT-PCR) and Western blot, respectively. Our results show that Rh2
dose-dependently (30–60 µM) inhibited cell differentiation in 3T3-L1 cells (44.5% ± 7.8% of control
at 60 µM). This inhibitory effect is accompanied by the attenuation of the protein and/or mRNA
expression of adipogenic markers including PPAR-γ and CCAAT/enhancer binding protein alpha,
fatty acid synthase, fatty acid binding protein 4, and perilipin significantly (p < 0.05). Moreover,
Rh2 significantly (p < 0.05) inhibited differentiation in human primary preadipocytes at much lower
concentrations (5–15 µM). Furthermore, dietary intake of Rh2 (0.1 g Rh2/kg diet, w/w for eight weeks)
significantly (p < 0.05) reduced protein PPAR-γ expression in liver and hepatic glutathione reductase
and lowered fasting blood glucose. These results suggest that ginsenoside Rh2 dose-dependently
inhibits adipogenesis through down-regulating the PPAR-γ pathway, and Rh2 may be a potential
agent in preventing obesity in vivo.
Keywords: ginsenoside Rh2; adipogenesis; PPAR-γ pathway; preadipocytes; obese mice

1. Introduction
Ginseng (Panax ginseng) has been used as a medicinal herb and functional food in Asia for
over 2000 years [1], and it is the fifth most commonly used natural product in the United States [2].
There are four major ginsengs according to the preparation method: fresh ginseng, white ginseng
(dehydration of fresh ginseng using sunlight), red ginseng (steaming dry/fresh ginseng at 95–100 ◦ C
for a reasonable time), and black ginseng (nine-time repetitive steaming white ginseng at 95–100 ◦ C
for 3 h) [3]. Red ginseng, the most attractive ginseng, accounting 59% in the South Korean market,
is believed to have better health benefits than fresh ginseng and white ginseng, because more saponins
and ginsenosides—the bioactive components of ginseng—are produced by the heating process.
Particularly, ginsenosides such as Rg3 and Rh2, which are trace or not detectable in fresh or white
ginseng, are dramatically increased by this process in red ginseng. This ginsenoside Rg3 can be
transformed to ginsenoside Rh2 by intestinal bacteria or thermal process [4–6]. Both Rg3 and Rh2
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have been reported to have special health benefits, including anticancer [7–9], anti-diabetes [10,11],
anti-Alzheimer disease [12], and anti-inflammation [13].
Recently, the anti-obesity effect of ginseng has been extensively investigated [14] because of
the worldwide fast increasing obesity prevalence. For instance, Korean red ginseng extracts (200 mg/kg,
i.p. for three weeks) reduced food intakes and decreased the levels of leptin and neuropeptide Y
in high-fat diet-fed rats [15]. American ginseng berry juice (oral gavage, once a day, 0.6 mL/kg for
10 days) reduced body weight gain in mice [16]. While the anti-obesity effects of ginseng crude
extracts/juice have been reported in cells and animals, the only two reports of Rh2 on obesity are
controversial. Rh2 promotes fat accumulation at low concentrations (0.01–1 µM) by activating
glucocorticoid receptor in 3T3-L1 cells [17]; however, at a high level (at 20 and 40 µM), Rh2 attenuates
3T3-L1 cell differentiation [18]. This cell differentiation, named adipogenesis, plays a vital role in adult
and childhood obesity development [19,20]. In the present study, we hypothesized that ginsenoside
Rh2 inhibits adipogenesis through attenuating the peroxisome proliferator-activated receptor gamma
(PPAR-γ) pathway in preadipocytes. The objectives of the present study were to determine if (1) Rh2
dose-dependently attenuates preadipocytes differentiation both in rodent preadipocytes (3T3-L1 cells)
and human primary preadipocytes (HPPs); (2) dietary Rh2 intake prevents adipogenesis in obese
mice; and (3) Rh2 attenuates adipogenesis by PPAR-γ and CCAAT/enhancer binding protein (C/EBP)
pathway both in vitro and in vivo.
2. Results
2.1. Ginsenoside Rh2 Dose-Dependently Suppresses 3T3-L1 Differentiation without Cytotoxicity
Ginsenoside Rh2 (30, 40, 50, or 60 µM) was added in the medium from day 0 (adding differential
inducer 3-isobutyl-1-methylxanthine (IBMX) + dexamethasone + insulin (MDI)) and replaced on
day 3 and day 5 in 3T3-L1 cells. On day 7, cells were stained with Oil-Red O to take images or
extract fat by adding 100% isopropanol and measured the absorbance at 490 nm to evaluate the fat
accumulation. As showed in Figure 1A, Rh2 inhibited MDI-induced intracellular fat droplets formation
dose-dependently. At 60 µM, Rh2 reduced fat accumulation by up to 46% of the dimethyl sulfoxide
(DMSO) control. We did not show the data on concentrations of 1 µM, 10 µM, and 20 µM because
there were no significant effects on differentiation at these concentrations. The toxicity of ginsenoside
Rh2 was evaluated by the cell toxicity MTT assay. We found that there was no significant effect on
cell viability at the selected level of ginsenoside Rh2 (10–60 µM) in 3T3-L1 cells (Figure 1B). However,
cells were significantly killed at 80 µM, which is in line with the previous report that ginsenoside Rh2
exerted cellular toxicity at doses of 80–160 µM [18]. These results indicate that ginsenoside Rh2 can
prevent preadipocytes differentiation in a dose-dependent manner without cytotoxicity.
2.2. Ginsenoside Rh2 Dose-Dependently Inhibits PPAR-γ and C/EBP-α Protein Expressions in 3T3-L1 Cells
PPAR-γ and C/EBP-α are the two transcriptional factors of preadipocyte differentiation, and Rh2
suppressed 3T3-L1cells differentiation as above, we want to know if Rh2 affects protein level of
PPAR-γ and C/EBP-α during the differentiation process. The Western blot results showed that
MDI-induced PPAR-γ (Figure 2A) and C/EBP-α (Figure 2B) protein expressions were dose-dependently
reduced by Rh2 in 3T3-L1 cells, the same pattern of the inhibitory effect of Rh2 in fat accumulation
(Figure 1A). Particularly, protein expressions of PPAR-γ (Figure 2A) and C/EBP-α (Figure 2B) were
significantly reduced to 4.9% (p < 0.01) and 6.5% (p < 0.01) of DMSO, respectively, by Rh2 at 60 µM.
Therefore, ginsenoside Rh2 attenuates PPAR-γ and C/EBP-α protein expression, thereby inhibiting
the adipogenesis process.
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2.2. Ginsenoside Rh2 Dose-Dependently Inhibits PPAR-γ and C/EBP-α Protein Expressions in 3T3-L1 Cells
PPAR-γ and C/EBP-α are the two transcriptional factors of preadipocyte differentiation, and Rh2
suppressed 3T3-L1cells differentiation as above, we want to know if Rh2 affects protein level of
PPAR-γ and C/EBP-α during the differentiation process. The Western blot results showed that MDIinduced PPAR-γ (Figure 2A) and C/EBP-α (Figure 2B) protein expressions were dose-dependently
reduced by Rh2 in 3T3-L1 cells, the same pattern of the inhibitory effect of Rh2 in fat accumulation
(Figure 1A). Particularly, protein expressions of PPAR-γ (Figure 2A) and C/EBP-α (Figure 2B) were
significantly reduced to 4.9% (p < 0.01) and 6.5% (p < 0.01) of DMSO, respectively, by Rh2 at 60 μM.
Therefore, ginsenoside Rh2 attenuates PPAR-γ and C/EBP-α protein expression, thereby inhibiting
the adipogenesis process.
Figure 2. Ginsenoside Rh2 dose-dependently suppresses protein expressions of PPAR-γ (A)
Figure 2. Ginsenoside Rh2 dose-dependently suppresses protein expressions of PPAR-γ (A) and
and CCAAT/enhancer binding protein (C/EBP)-α (B) in 3T3-L1 cells. On day 7, cells treated with
CCAAT/enhancer binding protein (C/EBP)-α (B) in 3T3-L1 cells. On day 7, cells treated with various
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concentrations
of and
Rh2 C/EBP-α
were collected
measure peroxisome
proliferator-activated
receptor
gamma
gamma
(PPAR-γ)
proteintoexpressions
by Western
blotting and normalized
by β-actin
(PPAR-γ)
and
C/EBP-α
protein
expressions
by
Western
blotting
and
normalized
by
β-actin
expression. Values are means ± SE, n = 3. A set of representative images and bar graphs are shown.
* expression.
p < 0.05, ** pValues
< 0.01are
vs. means
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p < 0.05, ** p < 0.01 vs. DMSO.

2.3. Ginsenoside Rh2 Abolishes MDI-Induced PPAR-γ mRNA Expression in 3T3-L1 Cells
Although Rh2 abolished MDI-induced PPAR-γ protein expression, it is worth investigating
whether the inhibitory effect of Rh2 on this key molecule is via a transcriptional mechanism. We
measured PPAR-γ mRNA expression in 3T3-L1 cells using quantitative real-time polymerase chain

CCAAT/enhancer binding protein (C/EBP)-α (B) in 3T3-L1 cells. On day 7, cells treated with various
concentrations of Rh2 were collected to measure peroxisome proliferator-activated receptor gamma
(PPAR-γ) and C/EBP-α protein expressions by Western blotting and normalized by β-actin
expression. Values are means ± SE, n = 3. A set of representative images and bar graphs are shown. *
p < 0.05,
< 0.01 vs. DMSO.
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Figure 3. Ginsenoside Rh2 reduces PPAR-γ mRNA expression in 3T3-L1 cells. On day 7, cells treated
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2.4. Ginsenoside Rh2 Attenuates Fat Packing Proteins in 3T3-L1 Cells

2.4. Ginsenoside
Rh2
Fatof
Packing
Proteins which
in 3T3-L1
Cells
Fat packing
is aAttenuates
critical step
adipogenesis,
is implemented
by several packing proteins
including fatty acid synthase (FAS), fatty acid binding protein 4 (FABP4), and perilipin. We found
that ginsenoside Rh2 dose-dependently inhibited protein expression of perilipin (Figure 4A), FAS
(Figure 4B), and FABP4 (Figure 4C) on day 7 in 3T3-L1cells. These results matched the patterns of
the Rh2 inhibitory effects on fat accumulation, PPAR-γ, and C/EBP-α protein and mRNA expressions
in 3T3-L1 cells, as aforementioned.
2.5. Ginsenoside Rh2 Dose-Dependently Inhibits Cell Differentiation in Human Primary Preadipocytes
Although Rh2 dose-dependently inhibited cell differentiation and relevant key molecules’
expression in 3T3-L1 cells, the high concentrations (30–60 µM) of Rh2 and the characteristics of
the 3T3-L1 cell line [21] prevent the application of Rh2 to fight obesity in humans. We recently
reported that human primary preadipocytes (HPPs) were more sensitive and required much lower
concentrations of the drugs than 3T3-L1 cells in the anti-adipogenic effect [22]. Indeed, compared
with the effective concentrations (30–60 µM) in 3T3-L1 cells, 5–15 µM Rh2 significantly inhibited
fat accumulation in HPPs (Figure 5). This was also demonstrated in the anti-adipogenic effect of
ginsenoside Rg3 between HPPs and 3T3-L1 cells in our recent study [23]. These results suggest that
Rh2 has the potential to exert the anti-adipogenic effect in humans.
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2.5. Ginsenoside Rh2 Dose-Dependently Inhibits Cell Differentiation in Human Primary Preadipocytes
Although Rh2 dose-dependently inhibited cell differentiation and relevant key molecules’
expression in 3T3-L1 cells, the high concentrations (30–60 μM) of Rh2 and the characteristics of the
3T3-L1 cell line [21] prevent the application of Rh2 to fight obesity in humans. We recently reported
that human primary preadipocytes (HPPs) were more sensitive and required much lower
concentrations of the drugs than 3T3-L1 cells in the anti-adipogenic effect [22]. Indeed, compared
with the effective concentrations (30–60 μM) in 3T3-L1 cells, 5–15 μM Rh2 significantly inhibited fat
accumulation in HPPs (Figure 5). This was also demonstrated in the anti-adipogenic effect of
ginsenoside Rg3 between HPPs and 3T3-L1 cells in our recent study [23]. These results suggest that
Rh2 has the potential to exert the anti-adipogenic effect in humans.

Figure 5. Ginsenoside Rh2 dose-dependently reverses lipid accumulation, protein expressions of
Figure 5. Ginsenoside Rh2 dose-dependently reverses lipid accumulation, protein expressions of
differentiation markers in human primary preadipocytes (HPPs). The cells stained with Oil-red O on
differentiation markers in human primary preadipocytes (HPPs). The cells stained with Oil-red O on
day 15 were dissolved in isopropanol, and fat accumulation was measured by absorbance using Synergy
day 15 were dissolved in isopropanol, and fat accumulation was measured by absorbance using
H1 hybrid reader at 490 nm. Oil-Red O representative images of lipid accumulation and the average
Synergy H1 hybrid reader at 490 nm. Oil-Red O representative images of lipid accumulation and the
bar graph are shown (40 × magnification). Values are means ± SE, n = 4. A set of representative images
average bar graph are shown (40 × magnification). Values are means ± SE, n = 4. A set of representative
and bar graphs are shown. * p < 0.05, ** p < 0.01 vs. DMSO.
images and bar graphs are shown. * p < 0.05, ** p < 0.01 vs. DMSO.

2.6. Dietary Ginsenoside Rh2 Reduces Hepatic PPAR-γ Expression in Obese Mice
Because of the complexity of the absorption and metabolism of Rh2, it is essential to test whether
dietary supplementation of Rh2 can inhibit PPAR-γ expression, and thereby prevent obesity in ob/ob
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2.6. Dietary Ginsenoside Rh2 Reduces Hepatic PPAR-γ Expression in Obese Mice
Because of the complexity of the absorption and metabolism of Rh2, it is essential to test whether
dietary supplementation of Rh2 can inhibit PPAR-γ expression, and thereby prevent obesity in ob/ob
obese mice, a widely used obese animal model. As shown in Figure 6A, dietary intake of Rh2
(0.1 g Rh1/kg diet, w/w, for eight weeks) significantly reduced protein PPAR-γ expression in the liver,
the primary organ of adipogenesis, although we did not found a significant change of PPAR-γ expression
in white adipose tissues (WATs). The fasting glucose was significantly reduced by Rh2 at the end of
the experiment (Table 1), although we did not observe significant changes in the body weight, food
intake, weight of the liver, and weight of WATs, as well as glucose tolerance (data not shown) by Rh2.
Moreover, levels of hepatic glutathione reductase (GR) and glutathione S-transferase (GST), two major
antioxidants molecules, were significantly decreased in the Rh2 group (Table 2). These enzymes
are significantly increased in obese animals fed with high-fat diets and contribute to obese-induced
complications. Similarly, the obese-increased hepatic GR and GST were reversed by dietary intake of
grape seed extract in obese rats [24], which might be because of the oxidative stress-reducing capacity
and inhibition of the generation of superoxide anions and hydroxyl-free radicals.
Table 1. Bodyweight gain, food intake, weight of liver, weight of white adipose tissues (WATs), fasting
blood glucose, and hepatic antioxidants in obese mice.
Group

Body Weight
Gain (g/mouse)

Food Intake
(g/mouse/day)

Liver
Weight (g)

WATs
Weight (g)

Fasting Blood
Glucose
(mg/dL)

Liver Glutathione
Reductase
(nmol/min/mg protein)

Liver Glutathione
S-Transferase
(nmol/min/mg protein)

SD
Rh2

21.6 ± 1.85
24.1 ± 0.82

3.85 ± 0.30
3.82 ± 0.30

1.78 ± 0.22
1.67 ± 0.23

2.71 ± 0.31
2.69 ± 0.39

160 ± 16.9
132 ± 11.4 *

50.2 ± 3.77
38.7 ± 0.91 *

1171 ± 53.3
1044 ± 17.2 *

Values are means ± SE, n = 12. * p < 0.05 vs. standard diet (SD).
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accumulation and expressions of PPAR-γ, C/EBP-α, FAS, and perilipin in 3T3-L1 cells. Compared
with the required high Rh2 concentrations (30–60 μM) in 3T3-L1 cells, Rh2 significantly inhibited
differentiation at much lower levels (5–15 μM) in HPPs. The different effective dosages in 3T3-L1
cells and HPPs may be the result of the different characteristics of these two cells that 3T3-L1 cells are
from a homogeneous population, but HPPs include both preadipocytes and fibroblast-likes cells, as
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concentrations (30–60 µM) in 3T3-L1 cells, Rh2 significantly inhibited differentiation at much lower
levels (5–15 µM) in HPPs. The different effective dosages in 3T3-L1 cells and HPPs may be the result of
the different characteristics of these two cells that 3T3-L1 cells are from a homogeneous population, but
HPPs include both preadipocytes and fibroblast-likes cells, as we discussed [23]. These results confirm
our research hypothesis that ginsenoside Rh2 inhibits adipogenesis through attenuating the PPAR-γ
pathway in both preadipocytes and obese mice.
Ginsenoside Rh2 was not detected in red and black Asian ginseng, while Rg3 was increased by
this process [25,26]. In American ginseng, Rh2 is not naturally present in both root and leaf; however,
heat treatment (100 ◦ C, 1.5 h) produced 11.3 ± 0.5 mg/g Rh2 in leaf, but not from heat-treated root [6].
Another study found that a total of 576 mg/g Rh2 (20(R)-Rh2 + 20(S)-Rh2) can be extracted in American
ginseng leaf by the heat extracting process (100 ◦ C, 1.5 h) [27]. However, one study found that Rh2
was not detectable in white Asian ginseng, but was detected in white American ginseng (0.007%),
and long-time steaming remarkably increased Rh2 level (0.066% after 4 h steaming) in American
ginseng [28]. Moreover, Rh2 can be hydrolyzed from Rg3 in the digestive system, and the maximum
plasma concentration of Rh2 of 0.48 µM can be reached in 2 h after oral ginsenoside Rg3 (50 mg/kg) in
normal rats [4]. In addition, this degrading process from Rg3 to Rh2 can be suppressed by a tumor
in rats [4]. In humans and rats, Rh2 was transformed by intestinal bacteria from Rg3, which was
metabolized in the stomach from Rb1 and Rb2, the major naturally presented ginsenosides in fresh
ginseng [5,29]. Protopanaxadiol and monooxygenated protopanaxadiol are the metabolites of Rb1,
Rg3, and Rh2 in rat feces [29]. Therefore, gut microbiota plays a crucial role in Rh2 conversion from
Rb1 and Rg3. In addition, Rh2 can be rapidly produced from Rb1 under the acidic environment
(simulated gastric fluid) [30]. Furthermore, the octyl ester derivative of Rh2 (Rh2-O) has a higher
cellular uptake (63.24%) than Rh2 (36.76%) when incubated with HepG2 cells for 24 h [10]. Therefore,
Rh2 is an intermediate ginsenoside from Rg3 or Rb1 by heating, intestinal bacteria, and gastric fluid,
and it has a low rate of cellular uptake, but with multiple beneficial effects.
Rh2 promoted fat accumulation at low concentrations (0.01–1 µM) by activating glucocorticoid
receptor in 3T3-L1 cells [17]; however, at the high level (at 20 and 40 µM), Rh2 attenuated 3T3-L1cell
differentiation via activating the adenosine monophosphate (AMP)-activated protein kinase (AMPK)
signaling pathway [18]. Our results are in line with this study finding that Rh2 dose-dependently
(30–60 µM) inhibited fat accumulation, and accompanied by the attenuated expressions of critical
markers of PPAR-γ, C/EBP-α, FAS, FABP4, and perilipin. The different effect of low level of Rh2
(1 µM) between Niu et al. [17] and our study and Hwang et al. [18] is the result of different
conditions (no chemical inducer versus cocktail MDI mixture (0.5 mM IBMX, 1 µM dexamethasone,
and 10 µg/mL insulin)), and the powerful MDI inducer produced strong differentiation overshadows
the pro-adipogenesis effect of Rh2 at this low level. We also tested the toxicity of Rh2 using an MTT
assay that all concentrations (30–60 µM) having anti-adipogenic effects are safe in 3T3-L1 cells.
AMPK is a key regulator of energy dynamics, and it produces ATP and enhances oxidative
metabolism and mitochondrial biogenesis, adipogenesis, as well as lipolysis [31–33]. Overexpression
of AMPK in mice induces the expression of genes controlling lipid oxidation and mitochondrial [34,35].
Activated AMPK may reduce PPAR-γ activity and expression in adipocytes [36], and this is supported by
the study that Rh2 attenuated 3T3-L1cell differentiation via activating the AMPK signaling pathway [18].
Indeed, red ginseng [37–39] and Rg3, the source of Rh2, all activated AMPK activity [40–42]. Hence,
this Rh2-activated AMPK may prevent/reduce obesity by increasing energy expenditure and inhibiting
adipogenesis. Moreover, the anti-adipogenic effect of Rh2 may depend on phosphoinositide 3-kinase
(PI3K)/Akt pathways and wingless-type MMTV integration site (WNT)/β-catenin pathway, which is
supported by the fact that the AKT [43] and (WNT)/β-catenin pathways [44] are involved in adipogenesis
and Rh2 can significantly affect these pathways [45,46].
There is no report that individual dietary Rh2 prevents obesity in animals, although red ginseng
crude extract has been reported in preventing obesity in rodent models by reducing leptin level
and adipogenesis level [47–49], as well as enhancing fatty acid oxidation and energy expenditures
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via activation of PPARα in rats (200 mg/kg to 10-week-old, for 32 weeks) [50]. In the present study,
we found that dietary intake of Rh2 (0.01%, w/w) significantly reduced PPAR-γ protein expression
in liver, fasting blood glucose, and two major endogenous antioxidant molecules GR and GST in
ob/ob mice, although we did not observe significant changes of body weight, food intake, and fat pad.
These results indicate that Rh2 has the potential to fight obesity, at least in the liver, the factory of
fat and energy metabolism. Indeed, the prevalence rate of nonalcoholic fatty liver disease (NAFLD)
increases with increasing body mass index (BMI). For instance, the prevalence rates of NAFLD are 15%,
65%, and 85% in nonobese, obese (BMI 30.0–39.9 kg/m2 ), and extremely obese patients (BMI 40 kg/m2 ),
respectively [51]. However, because of the limited resources, the only one low dosage (0.01%, w/w)
Rh2 was used in this animal study, which may contribute to the failure of reducing weight gain and fat
pads as well as the expression of adipogenic markers including PPAR-γ, C/EBP-α, FAS, and perilipin
(which have been confirmed in 3T3-L1 cells). In addition, we did not analyze the adipocyte sizes in
WATs because there were no significant changes in body weight and WATs’ weight in obese mice.
The Rh2 level in the blood of mice was not measured because of the limited volume of collected blood.
If several different higher dosages are used in the next study, and these limitations will be solved,
we can make a conclusion on whether the dietary intake of Rh2 prevents obesity in animals.
In summary, we found that Rh2 dose-dependently inhibited cell differentiation and expressions of
adipogenic markers including PPAR-γ, C/EBP-α, FAS, and perilipin in 3T3-L1 cells. HPPs need much
lower concentrations of Rh2 in inhibiting differentiation compared with 3T3-L1 cells. This is the first
study to find that dietary supplementation Rh2 attenuated hepatic protein expression of PPAR-γ,
a key regulator of adipogenesis and fat metabolism, as well as the improvements in fasting blood
glucose and hepatic antioxidants GR and GST in obese mice. These results suggest that ginsenoside
Rh2 dose-dependently inhibits preadipocytes differentiation through down-regulating the PPAR-γ
pathway, and Rh2 may be a potential agent in preventing obesity, although more studies are needed.
4. Materials and Methods
4.1. Chemicals
The HPPs specific medium fibroblast basal medium plus fibroblast growth kit, serum-free
(KS-201-040), was also obtained from ATCC (Manassas, VA, USA). Dulbecco’s modified Eagle’s
medium and penicillin-streptomycin were from Gibco (Grand Island, NY, USA). Fetal bovine serum
was purchased from Mediatech (Manassas, VA, USA). Ginsenoside Rh2 (99.9% purity) was purchased
from ChromaDex (Irvine, CA, USA) and was dissolved in DMSO, aliquots at 100 mM, and stored in
a −20 ◦ C freezer. Insulin from Roche (Mannheim, Germany) and 3-isobutyl-1-methylxanthine (IBMX),
dexamethasone, and rosiglitazone from Sigma-Aldrich (St Louis, MO, USA) were used to induce
adipocyte differentiation. Specific antibodies for β-actin, C/EBP-α, FABP4, FAS, PPAR-γ, and perilipin
were purchased from Cell Signaling Technology (Danvers, MA, USA). RNeasy Mini Kit was purchased
from Qiagen (Valencia, CA, USA) and iTaq Universal SYBR Green One-Step Kit was purchased from
Bio-Rad (Hercules, CA, USA). SuperSignal West Dura chemiluminescence kit was from ThermoFisher
Scientific (Fair Lawn, NJ, USA). TACS MTT cell proliferation assay kit was purchased from Trevigen
(Gaithersburg, MD, USA). Dimethyl sulfoxide (DMSO) was purchased from Sigma (St Louis, MO,
USA), while 10% buffered formalin phosphate and 2-propanol were purchased from Fisher Scientific
(Fair Lawn, NJ, USA). Oil-red O solution was purchased from Electron Microscopy Science (Hatfield,
PA, USA).
4.2. Cell Differentiation
3T3-L1 preadipocytes (from ATCC, Manassas, VA, USA) were cultured in 12-well plates with
Dulbecco’s modified Eagle medium (DMEM) high glucose containing 1% penicillin-streptomycin (PS)
and 10% fetal bovine serum (FBS). To induce differentiation, two-day post-confluent preadipocytes
were changed with cultural medium (DMEM with 1% PS and 10% FBS) supplemented with cocktail
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mixture (MDI: 0.5 mM IBMX, 1 µM dexamethasone, and 10 µg/mL insulin) on day 0. After three days,
the cells were then maintained in normal cultural medium with 10µg/mL insulin. The 3T3-L1 cells need
seven days to accomplish the differentiation process. Meanwhile, the cells were treated with various
concentrations of Rh2 during the whole differentiation process from day 0 to day 7, as previously
described [52]. Passages between 5 and 25 of 3T3-L1 cells were used in all experiments.
Human primary preadipocytes (HPPs, from ATCC, Manassas, VA, USA) were maintained at 37 ◦ C
and 5% CO2 in fibroblast basal medium plus fibroblast growth kit-serum-free (ATCC, KS-201-040)
with biotin (33 µM) and pantothenate panthothenate (17 µM). After full confluent, cell differentiation
(day 0) was induced with a hormone cocktail containing 0.5 mM IBMX, 1 µM dexamethasone, 1 µM
rosiglitazone, and 10 µg/mL insulin in the growth medium. After three days, the medium was changed
to normal growth medium containing 10 µg/mL insulin every three days until day 15. The cells were
treated with various concentrations of Rh2 during the whole differentiation process from day 0 to day
15, as we described [22]. Passages between 3 and 6 of HPPs were used in all experiments.
4.3. Oil-Red O Staining
To determine the adipogenesis and fat accumulation in the adipocytes, 3T3-L1 cells (day 7)
and HPPs (day 15) were stained with Oil-red O. The cells were gently washed with phosphate-buffer
saline (PBS) once and fixed with 10% formalin for 1 h at 4 ◦ C. The fixed cells were washed with PBS
three times. The cells were then stained with filtered Oil-red O solution for 30 min at room temperature
and then washed five times with water to remove the unstained Oil-red O solution. Fat droplets in
the adipocytes were stained as red; images were taken under an optical microscope. The relative fat
accumulation has dissolved the dye in 100% isopropanol and measured using a Synergy H1 hybrid
reader (BioTek Instruments, Inc. Winooski, VT) at 490 nm, as we described [22].
4.4. Cell Viability Assay
To test whether Rh2 directly kills cells at the selected concentrations, TACS MTT cell proliferation
assay (Trevigen, Gaithersburg, MD, USA) was conducted to evaluate cell viability according to
the manufactory’s instruction, as we described [23]. Briefly, 3T3-L1 cells were seeded in 12-well plates
(about 20% confluent) with different dosages of Rh2 from 30 µM to 300 µM for 72 h. Cells were then
incubated with MTT reagent (100 µL per well) for 4 h and added detergent reagent (500 µL each
well) and incubated in the dark for 4 h. The relative cell viability was determined by the absorbance
at 570 nm using a Synergy H1 hybrid reader (BioTek Instruments, Inc. Winooski, VT).
4.5. Animals
Four-week-old male obese leptin-deficient mice (C57BL/6J-Lepob , ob/ob, Jackson Laboratory,
Bar Harbor, ME, USA) were randomly divided into two groups (12 mice/group), which were fed
with either AIN-93G mineral mix standard food (powder) [53], or standard food containing 0.01%
ginsenoside Rh2 (0.1 g Rh2/kg diet, w/w, mixed Rh2 with standard powder food, and fed in food jar) for
eight weeks. This dosage was calculated based on previous whole ginseng extracts in animals [47–50],
and our in vitro studies (0.5% whole ginseng extracts × 20% of Rb1 on the whole extracts = 0.01%).
The detailed compositions of diets are listed in Table 2. All animals were maintained at constant
temperature and humidity with a 12:12 h light/dark cycle permitted consumption of water and food
ad libitum. Bodyweight and food intake were measured weekly throughout the study. At the end
of the study, all mice were fasted overnight and euthanized with CO2 , according to the American
Veterinary Medical Association guidelines. Blood, liver, and fat tissues were collected and prepared for
blood glucose, antioxidant activity, and relevant biomarkers analyses. All experimental procedures
were approved by the Institutional Animal Care and Use Committee at Tennessee State University
following the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
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Table 2. Compositions of standard AIN-93G diet and Rh2 supplemented diet.
Ingredient

Standard Diet (g/kg diet)

Rh2 Supplemented Diet (g/kg diet)

Cornstarch
Casein (>85%protein)
Dextrinized cornstarch (>90% tetrasaccharides)
Sucrose
Soybean oil
Fiber
Mineral mix (AIN-93M-MX)
Vitamin mix (AIN-93-vx)
L-Cystine
Choline bitartrate
Ter-butyhydroquinone
Ginsenoside Rh2
Total

466
140
155
100
40.0
50.0
35.0
10.0
1.80
2.50
0.008
0.00
1000

466
140
155
100
40.0
50.0
35.0
10.0
1.80
2.50
0.008
0.10
1000

4.6. Protein Extraction
At the end of the differentiation process with/out treatments, 3T3-L1 cells and HPPs were collected
to extract proteins, as we described [23]. Briefly, cells were rinsed once with PBS and added with
mammalian protein extraction buffer. Cells were then scraped off and collected in 1.5 mL tube
and sonicated on ice for 15 s three times, with a 15 s interval. After centrifuging 10 min at 12,000× g,
the supernatant was collected as a protein sample. Sample protein concentration was measured using
a Pierce BCA protein assay kit. An equal amount of protein of samples was mixed with 2× Western
blot sample buffer and heated at 95 ◦ C for 5 min, and then subjected to Western blot analysis.
Animal tissues liver or white adipose tissues (WATs) collected from the in vivo study were
weighted (about 50 mg each mouse) and added in mammalian protein extraction buffer with proteinase
inhibitor cocktail (Sigma-Aldrich). After cutting 30 times, samples were homogenized by the Precellys
24 tissue homogenizer on ice three times, 15 s each time. Then, samples were centrifuged 10 min
at 12,000× g, and supernatants were collected as protein sample. For fat tissue, about 20 mg fat was put
into the specific adipose tissue protein extraction buffer (HEPES, 50 mM; NaCl, 150 mM; glycerol, 10%;
Triton X-100, 1%) with proteinase inhibitor cocktail (Sigma-Aldrich). After 30 times cutting, samples
were homogenized by Precellys 24 tissue homogenizer on ice three times, 15 s each time. Then, samples
were centrifuged 20 min at 18,000× g at 4 ◦ C. After removing the fat cake from the top, the supernatant
was transferred to a new tube as a protein sample. Sample protein concentration was measured using
a Pierce BCA protein assay kit. The samples were directly used to measure antioxidant levels as below.
For Western blot, the normalized protein samples were mixed with 2 × Western blot sample buffer
and heated at 95 ◦ C for 5 min, and then subjected to Western blot analysis.
4.7. Western Blot
Protein samples from cultured cells and animal tissues were analyzed by Western blot, as we
described [23]. Briefly, samples were separated by 10% SDS-PAGE, and the membrane was blocked
for 1 h with Tris-buffered saline-Tween (TBST) containing 5% skim milk at room temperature. After
washing 3 times with TBST, the membrane was incubated with the relevant primary antibody at 4 ◦ C
overnight. On the next day, the membrane was washed three times with TBST and then incubated with
secondary antibody for one hour at room temperature. Specific bands were detected by SuperSignal
West Dura chemiluminescence (ThermoFisher Scientific), and visualization was performed by exposure
of the membranes to X-ray films. Band intensities were quantified by ImageJ software. The value of
the specific protein was normalized by the expression of β-actin and expressed as the percentage of
the control.
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4.8. Total RNA Isolation and Quantitative Real-Time PCR Analysis
At the end of the adipogenic process, total RNA from 3T3-L1 adipocytes was isolated using
the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), as we described [23]. According to the manufacturer’s
instructions, 30 ng sample of total RNA was applied in the real-time quantitative PCR (SYBR green)
analysis using a Bio-Rad iTaq Universal SYBR Green One-step Kit. Designed primers were as follows:
PPAR-γ forward: TCG CTG ATG CAC TGC CTA TG, PPAR-γ reverse: GAG AGG TCC ACA GAG
CTG ATT [54]; β-actin forward: AGC CTT CCT TCT TGG GTA TGG, β-actin reverse: CAC TTG CGG
TGC ACG ATG GAG [55]. The optimized reaction cycles: cDNA synthesis 10 min at 50 ◦ C, reverse
transcriptase inactivation 5 min at 95 ◦ C, 45 cycles for PCR and detection, 10 s at 95 ◦ C, and 30 s
at 60 ◦ C. Relative gene expression was normalized by the β-actin expression and calculated using
the 2−∆∆Ct method.
4.9. Hepatic Antioxidants
Extracted liver protein samples from above were used to evaluate levels of antioxidants glutathione
reductase (GR) and glutathione S-transferase (GST) using a colorimetric detection assay kit according
to the manufacturer’s instructions (Cayman Chemicals). Briefly, the samples were treated with
metaphosphoric acid and triethanolamine to remove protein to avoid interferences owing to particulates
and sulfhydryl groups on proteins in the assay. Then, 50 µL of the sample was added with assay cocktail
and incubated for 25 min; concentrations of GR and GST were measured at 405 nm and calculated
from the standard curve, as previously described [56]. Samples were tested in duplicate using Synergy
H1 hybrid reader (BioTek Instruments, Inc. Winooski, VT). The value was normalized by the protein
level and expressed as nmol/min/ mg protein.
4.10. Statistical Analyses
All values of in vitro studies were presented as means ± SEM of at least three independent
experiments performed in triplicate. For the animal study, 12 mice/group was determined by
conducting a power analysis (using GPOWER software) for a one-way analysis of variance (ANOVA)
at a type error level of 5%. The values of in vivo studies were presented as means ± SEM of 12 mice.
All data were analyzed with one-way ANOVA and significant differences between treatment groups
were further analyzed using Tukey test. Differences with a p-value < 0.05 were considered significant.
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